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Abstract
Objective: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor imatinib, the development of 
resistance against imatinib has been observed. The most important mechanisms known to cause resis-
tance are point mutations in the ABL tyrosine kinase and the ATP domain. This study describes the 
use of denaturing high performance liquid chromatography (dHPLC) as a method to screen for muta-
tions of the ABL gene.
Material and Methods: We used the dHPLC based assay for the screening of ABL point mutations. 
Forty chronic myeloid leukemia (CML) patients who showed resistance to imatinib were screened in 
parallel by dHPLC and direct sequencing.
Results: Nine of the 40 patients (23%) had mutations. 
Conclusion: dHPLC can be a useful method for pre-screening. Analyzing the mutations and monitor-
ing (high-risk) patients can improve their prognosis and survival rate. dHPLC can potentially become 
a valuable tool for regular testing of patients in the future. (Turk J Hematol 2011; 28: 97-102)
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Özet
Amaç: Bir BCR-ABL tirozin kinaz inhibitörü olan imatinib’in etkinliğine karşın bazı hastalarda ilaca karşı 
direnç gelişimi gözlenmektedir.. Direnç gelişimine neden olan en önemli mekanizma, ABL geninin tirozin 
kinaz ve ATP bölgelerindeki nokta mutasyonlarıdır. Bu çalışma ABL gen mutasyonlarının taranmasında 
denatüre edici HPLC (dHPLC) yönteminin yerini ve önemini açıklama amacıyla yapılmıştır. 
Yöntemler ve Gereçler: ABL nokta mutasyonları, dHPLC kullanılarak taranmıştır. Imatinib direnci 
gösteren 40 KML hastası DHPLC ve paralelinde doğrudan sekanslama ile incelenmiştir.
Bulgular: Kırk hastanın dokuzunda (%23) mutasyon saptandı.Introduction
Chronic myeloid leukemia (CML) is a prolifera-
tive stem cell disorder that affects patients in all age 
groups [1,2]. The clinical course of CML is charac-
teristically triphasic, starting with a chronic phase 
(CP) of variable duration, followed by progression 
to an accelerated phase (AP) and finally resulting in 
blast crises (BC) [3-5]. CML is the first discovered 
human cancer associated with a consistent chro-
mosomal abnormality-the chimeric BCR/ABL gene, 
known  as  Philadelphia  (Ph)  chromosome  [6,7]. 
This translocation causes an unregulated tyrosine 
kinase activity and has a pivotal role in CML patho-
genesis. Approximately 95% of CML patients have 
BCR/ABL rearrangement, indicating it is a suitable 
drug target for anticancer therapy [8,9]. 
Imatinib mesylate (IM) is a potent and selective 
inhibitor of BCR-ABL tyrosine kinase, the first rationally 
designed, molecularly targeted therapy for a human 
malignancy [10-13]. Despite the high rates of hemato-
logic and cytogenetic responses, some patients show 
IM resistance in both phases. Resistance to IM can be 
defined  as  the  lack  of  complete  hematological 
response  in  patients  with  CP  disease  or  as  lack  of 
return to CP for patients in an AP or BC [14,15]. 
Several underlying mechanisms for IM resistance 
have been studied in CML patients and cell lines. 
Drug  resistance  has  mostly  arisen  as  a  result  of 
point mutations in the BCR-ABL gene that reduce 
drug binding within the kinase domain or due to 
overexpression of BCR-ABL protein [15-18]. In clon-
al selection, BCR-ABL mutated cells have a higher 
survival rate due to the selective pressure of ima-
tinib  therapy.  A  number  of  mutations  have  been 
well characterized in terms of their ability and the 
degree to which they induce resistance [17,19-22]. 
Today, second-generation tyrosine kinase inhibitors 
(TKIs) have become available (Dasatinib, Sprycel, 
Bristol-Myers  Squibb;  Nilotinib,  Tasigna,  Novartis 
Pharma) in the market [23-25]. 
In  clinical  practice,  cytogenetic  monitoring  (as 
fluorescence in situ hybridization-FISH) and reverse 
transcription  quantitative  polymerase  chain  reac-
tion (RQ-PCR) have become gold standard monitor-
ing  assays,  and  they  are  becoming  increasingly 
standardized  between  laboratories  [26-28]. 
Furthermore, CML treatment should be monitored 
correctly and cABL kinase domain mutations should 
be  investigated.  However,  there  are  no  widely 
accepted guidelines at present for the screening of 
Ph+CML mutations [18,26,28]. Therefore, we report 
here the use of denaturing high performance liquid 
chromatography (dHPLC) and sequencing methods 
to screen for mutations in the nucleotide binding 
loop (P-loop), the catalytic domain and the activa-
tion loop of the ABL gene. 
Materials and Methods
Patients 
Peripheral  blood  (PB)  samples  were  obtained 
from  40  imatinib-resistant  or  -intolerant  CML 
patients, who were diagnosed between 1999 and 
2007 in the Adult Hematology Division of Istanbul 
Medical Faculty, Istanbul. All patients showed resis-
tance to 400 mg/day imatinib. Imatinib resistance 
was defined as inadequate initial response or loss 
of hematologic or cytogenetic response at any time 
during the treatment. All of the patient’s materials 
were stored at -80°C after homogenization in RLT 
buffer (Qiagen, GmbH, Germany). One PB sample 
from a CML patient known to be wild-type for ABL 
mutations  was  used  as  a  negative  control.  We 
obtained written informed consents from all patients
RNA isolation and cDNA synthesis
Total RNA was isolated by Qiagen RNeasy Protect 
kit (Qiagen, GnbH, Germany). RNA samples were 
treated with DNAse (1 U/µg) for the possible DNA 
contaminations during isolation. 1 µg of total RNA 
was used for cDNA synthesis by using random hex-
Sonuç: dHPLC yararlı bir ön tarama yöntemi olabilir. Mutasyon analizleri ile yüksek riskli hastaların 
monitörizasyonu  prognozu  iyileştirebilir  ve  sağ  kalım  oranını  arttırabilir.  Gelecekte  dHPLC  bu 
hastaların düzenli aralıklarla izleminde değerli bir araç olarak kullanılabilir.
(Turk J Hematol 2011; 28: 97-102)
Anahtar kelimeler: Kronik miyeloid lösemi, Imatinib direnci, mutasyon, dHPLC
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the protocol of the manufacturer (Fermentase).
Nested PCR and experimental design of 
dHPLC analysis
Mutation detection in the nucleotide binding loop 
(P-loop), the catalytic domain and the activation loop 
of  the  ABL  gene  was  performed  via  PCR-based 
dHPLC using a WAVE DNA fragment analysis system 
(Transgenomic). We used a nested-PCR approach for 
amplification of the ABL kinase domain with primers 
and PCR conditions described before [18]. First PCR 
was performed with 2 µl of cDNA and exons 12, 13 on 
BCR mRNA and exon 8 on ABL mRNA were ampli-
fied. The ABL kinase domain was divided into two 
partially  overlapping  fragments;  codons  206-  335 
(fragment B) and codons 262- 421 (fragment C) were 
amplified separately. This procedure ensures that the 
wild-type ABL transcript is not analyzed [18]. 
Using Wavemaker software (Transgenomic), we 
selected  optimal  temperatures  for  the  two  ABL 
mRNA fragments. Annealed PCR fragments (8-15 µl 
per sample) were injected into the DNASep HT car-
tridge for analysis at the following selected temper-
atures: Fragment B at 61.3, 62.3°C and fragment C at 
60.2, 61.1°C. 
Products were eluted at a constant flow rate of 
1.5 ml/min with a linear acetonitrile gradient deter-
mined by Navigator software (Transgenomic) based 
on the size and GC-content of the amplicon. The 
gradient was formed by combining buffer A (0.1M 
TEAA)  (Transgenomic)  and  Buffer  B  (0.1M  TEAA 
with 25% acetonitrile) (Transgenomic). The elution 
profiles  of  DNA  fragments,  monitored  by  the  sys-
tem’s UV detector, were used to produce chromato-
graphs. A wild-type sample was used as a negative 
control. Less stable heteroduplexes denature earli-
er than homoduplexes and, thus, appear first in elu-
tion  profiles.  Patients’  chromatograms  were  com-
pared with the wild-type profile, and samples with 
different characters (eluted before normal homo-
duplexes) were scored as positive. In addition to 
positive scored samples, crude PCR products from 
patients  scored  as  “negative”  were  also  directly 
sequenced to exclude the presence of undetected 
genetic variations. Sequences were compared with 
the  wild-type  sequence  and  analyzed  using  CLC 
combined Workbench software (V.3.6.1, Denmark).
Results
In this paper, we set up a straightforward, high-
throughput  dHPLC-based  assay  to  screen  for  the 
presence  of  mutations  in  the  catalytic  domain  of 
ABL tyrosine kinase of 40 Turkish CML patients with 
imatinib resistance. Nine of 40 patients (23%) had 
point mutations, and mutation characteristics of the 
patients  are  shown  in  Table  1.  Four  mutations 
(M244V, G250E, Y253H, V304I) fell within the nucle-
otide-binding loop (P-loop) that was involved in ATP 
binding. We observed that two mutations (F359C, 
K357R) affected the catalytic domain and two muta-
tions (T315I, F317L) were located in imatinib-bind-
ing residues. We identified two novel amino acid 
substitutions  (V304I,  K357R)  affecting  codons 
known as the hotspot region. Representative dHPLC 
chromatograms for fragments B and C are illustrat-
ed in Figure 1. 
Discussion
The basis of current therapy for CML in the CP 
includes the three TKIs - imatinib, dasatinib and nilo-
tinib - and allogeneic hematopoietic stem cell trans-
plantation  (allo-HSCT).  The  treatment  algorithm 
appears simple and easy to follow. Imatinib is the 
recommended  first-line  treatment  for  newly  diag-
nosed CP CML at an initial standard dose of 400 mg 
daily,  dasatinib  or  nilotinib  is  second  line,  and 
alloHSCT is for instances of failure of drug therapy. A 
partial guide to the choice of second-generation TKIs 
may be provided by the detection of some mutations 
[2,5,15,17-19,21,26].  Therefore,  it  is  recommended 
that molecular laboratories incorporate this analysis 
Table 1. BCR-ABL mutation characteristics of patients
Patient  Base change  Amino acid substitution  Status
ABL11  ACT>ATT  T315I  R
ABL13  TTC>TTG  F317L  R
ABL15  GGG>GAG, TTC>TGC  G250E, F359C  R
ABL16  ATG>GTG  M244V  R
ABL17  TAC>CAC  Y253H  R
ABL20  ACT>ATT  T315I  R
ABL25  TTC>TTG  F317L  R
ABL29  GTC>ATC  V304I  N
ABL34  TTC>TTG, AAA>AGA  F317L and K357R  R, N
R: Previously reported; N: Previously undescribed
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used direct sequencing and dHPLC. Direct sequenc-
ing is the most widespread method applied in the 
routine monitoring of patients. However, its sensitiv-
ity  is  low  (20%),  and  it  may  cause  false-negative 
results. Therefore, we used dHPLC technique, which 
has  a  sensitivity  of  1-5%  in  mutation  detection,  in 
addition to the sequencing [29-31]. 
We  found  BCR-ABL  mutations  localized  in  the 
P-loop, in the catalytic domain. The P-loop normally 
acts as nucleotide-binding loop for the phosphate 
groups of ATP , and its mutations are the most seri-
ous and common mutations. The catalytic domain 
is involved in the catalytic process [14-16,32-35]. In 
our study group, we detected (M244V, G250E, Y253H, 
V304I)  substitutions  in  P-loop  domain,  (K357R, 
F359C) mutations in catalytic domain and (T315I, 
F317L)  mutations  in  the  imatinib-binding  site. 
M244V, G250E, F317L, and F359C mutations might 
be  overcome  by  dose-escalation  [5,14,18,26,36]. 
However, Y253H mutation confers a highly resistant 
phenotype,  suggesting  withdrawal  of  imatinib  in 
favor  of  alternative  therapeutic  strategies  [18,26]. 
Two patients showed T315I mutation, which inter-
fered  with  a  critical  hydrogen  bond  that  forms 
between the ABL kinase and imatinib. It is known to 
be resistant to imatinib as well as the second-gener-
ation TKIs. Other than mutations, clinical relevance 
of other differences between dasatinib and nilotinib 
is unknown [5,26,36,37]. 
dHPLC is a sensitive and simple way to detect 
low level of mutations, based on differentiation in 
elution profiles. The results of the dHPLC showed 
several heteroduplex peaks on the chromatograms 
of samples (Figure 1). All abnormal elution profiles 
were  parallel  to  sequencing  results.  As  a  result, 
dHPLC seems to be a reliable method for use in the 
pre-screening  process.  Certainly,  the  sequencing 
must confirm a mutation and tell us the exact muta-
tion type.
Mutations  can  occur  among  imatinib-resistant 
and -intolerant patients, and sensitive detection of 
the  mutation  status  might  be  important  for  the 
patients who are resistant to imatinib. The European 
LeukemiaNET (ELN) recommends mutation analy-
sis in occurrences of suboptimal response or failure 
of 400 mg daily imatinib treatment. The suboptimal 
response  refers  to  no  cytogenetic  response  after 
three months of therapy, less than partial cytoge-
netic  response  after  six  months  of  therapy,  only 
achieving  a  partial  cytogenetic  response  at  12 
months of treatment, or less than major molecular 
response after 18 months of treatment. Furthermore, 
loss of the major molecular response at any time 
during the treatment or detection of a mutation is 
so-called  suboptimal  response.  Treatment  failure 
refers to not achieving a complete hematological 
response after three months of treatment, no cyto-
genetic response after six months of therapy, less 
than a partial cytogenetic response after 12 months 
of  treatment,  or  incomplete  cytogenetic  response 
after 18 months of treatment. Losing the complete 
hematological  response  or  complete  cytogenetic 
response  at  any  time  during  the  treatment  and 
detection of a mutation that is poorly sensitive to 
imatinib or the second- generation TKIs or clonal 
chromosome  abnormalities  are  also  considered 
failure. By determining the mutational status of a 
patient, the right therapy option (second-generation 
TKIs,  alloSCT,  experimental  drugs,  etc.)  can  be 
selected for each patient [38]. dHPLC system shows 
higher  sensitivity  (95-99%)  for  detecting  minor 
clones  in  the  mixed  follow-up  patient  samples. 
Conventional  direct  sequencing  has  lower  detec-
tion  sensitivity  to  perform  such  analysis  (about 
80-90%) [29,31]. Therefore, we suggest using dHPLC 
screening  as  a  routine  approach  to  screen  ABL 
kinase domain mutations, which can be confirmed 
by sequence analyses. 
Figure 1. dHPLC chromatograms and direct sequencing of mutant 
DNA for fragments B and C. (A) dHPLC profiles of two representative 
mutants overlaid with the wild-type profiles (left panel), fragment B 
at 61.3°C; (right panel); ACT>ATT, T315I. (B) dHPLC profiles of two 
representative mutants overlaid with the wild-type profiles (left pan-
el), fragment C at 60.2°C; (right panel); TTC>TGC, F359C
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